Cardiovascular Outcome Trials of GLP-1 RA in Patients With Type 2 Diabetes
| TRIAL, YEARS (REF.) | BASELINE PREVALENCE OF CVD/HF (PERCENT) | SAMPLE SIZE | DRUG AND DOSE VERSUS PLACEBO | HAZARD RATIO (95% CI) | |||
|---|---|---|---|---|---|---|---|
| Primary Endpoint | Hospitalization for HF | Worsening Nephropathy | |||||
| ELIXA, 2010–2015 (240) | 100 | 6,068 | Lixisenatide 10 mcg or 20 mcg per day | 4-point MACE: 1.02 (0.89–1.17) | 0.96 (0.75–1.23) | N/A | |
| LEADER, 2010–2015 (241) | 81 | 9,340 | Liraglutide 1.8 mg or max tolerated per day | 3-point MACE: 0.87 (0.78–0.97) | 0.87 (0.73–1.05) | 0.78 (0.67–0.92) | |
| SUSTAIN-6, 2013–2016 (242) | 72 | 3,297 | Semaglutide SQ 0.5 or 1 mg per week | 3-point MACE: 0.74 (0.58–0.95) | 1.11 (0.77–1.61) | 0.64 (0.46–0.88) | |
| EXSCEL, 2010–2017 (243) | 73 | 14,752 | Exenatide 2 mg per week | 3-point MACE: 0.91 (0.83–1.00) | 0.94 (0.78–1.13) | N/A | |
| HARMONY, 2015–2018 (244) | 100 | 9,463 | Albiglutide | 3-point MACE: 0.78 (0.68–0.90) | N/A | N/A | |
| REWIND, 2011–2018 (245) | 31 | 9,901 | Dulaglutide 1.5 mg per week | 3-point MACE: 0.88 (0.79–0.99) | 0.93 (0.77–1.12) | 0.85 (0.77–0.93) | |
| PIONEER-6, 2017–2018 (246) | 85 | 3,183 | Semaglutide oral 14 mg or max tolerated per day | 3-point MACE: 0.79 (0.57–1.11) | 0.86 (0.48–1.55) | N/A | |
| AMPLITUDE-O, 2018–2020 (247) | 90 | 4,076 | Efpeglenatide | 3-point MACE: 0.73 (0.58–0.92) | 0.61 (0.38–0.98) | 0.68 (0.57–0.79) | |
3-point MACE, major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke); 4-point MACE, (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina); AMPLITUDE-O, Effect of Efpeglenatide on Cardiovascular Outcomes; CI, confidence interval; CVD, cardiovascular disease; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HARMONY, Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease; HF, heart failure; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; PIONEER-6, Peptide Innovation for Early Diabetes Treatment; REWIND, Researching Cardiovascular Events With a Weekly Incretin in Diabetes; SUSTAIN-6, Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes.
SOURCE: References are listed within the table.
From: Heart Disease and Diabetes
Diabetes in America is in the public domain of the United States. You may use the work without restriction in the United States.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.